GlassScriptPhysician profile
Kalyan K Das
NPI 1124042916
$2,885.58
in general payments reported to CMS, 2019-2025
23 companies · $603 in 2025
The $603 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $471 · 2023: $856 · 2024: $955 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,414.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $414.09 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $362.16 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $291.27 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $241.20 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $207.14 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $182.73 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $164.86 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $141.60 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.64 | 2023-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $110.37 | 2022-2024 | Freestyle Libre 3 |
| Radius Health, INC. | $105.25 | 2024-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.90 | 2023-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.05 | 2023-2024 | Caplyta |
| Phathom Pharmaceuticals, INC. | $65.87 | 2024-2025 | Voquezna |
| Amgen INC. | $64.64 | 2023-2024 | Prolia, Evenity, Repatha |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $49.52 | 2022-2025 | Shingrix, Arexvy |
| Astellas Pharma US INC | $43.40 | 2023-2024 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $42.98 | 2025 | Auvelity |
| Actelion Pharmaceuticals US, INC. | $32.66 | 2024 | Opsumit, Uptravi |
| Biohaven Pharmaceutical Holding Company LTD. | $32.27 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.80 | 2022-2023 | |
| Grifols USA, LLC | $21.86 | 2024 | Prolastin-C Liquid |
| Molnlycke Health Care US, LLC | $17.32 | 2025 | Mepilex Border Sacrum, Mepilex Border Flex, Mepilex Border Post-Op Ag |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kalyan Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.